Novartis has developed Arcapta (indacaterol; marketed as Onbrez outside the US) for use in its Breezhaler/Neohaler dry-powder inhaler for the treatment of chronic obstructive pulmonary disease (COPD). As the first once-daily long-acting beta 2 agonist (LABA) to launch in the COPD market, Arcapta has seen high use as an add-on therapy to the gold-standard long-acting muscarinic antagonist (LAMA), Spiriva (tiotropium; Boehringer Ingelheim). Due to the increasing availability of fixed-dose LABA/LAMA combination therapies, including Sunovion and Novartis’s Utibron Neohaler ([indacaterol + glycopyrrolate]), and a number of triple-combination therapies having been launched, Datamonitor Healthcare does not forecast Arcapta to continue being used as an add-on therapy to Spiriva or other LAMA monotherapies. Instead, Arcapta is expected to be predominantly used as a monotherapy in mild and moderate patients.
LIST OF FIGURES
9 Figure 1: Arcapta for COPD – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Arcapta for COPD
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Arcapta for COPD
13 Figure 4: Arcapta Neohaler sales for COPD across Japan and the five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Arcapta drug profile
7 Table 2: Arcapta Phase III data in COPD
14 Table 3: Arcapta Neohaler sales for COPD across Japan and the five major EU markets, by country ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.